JP2018528200A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528200A5
JP2018528200A5 JP2018510406A JP2018510406A JP2018528200A5 JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5 JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5
Authority
JP
Japan
Prior art keywords
ring
independently
acceptable salt
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528200A (ja
JP6877407B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/048698 external-priority patent/WO2017035354A1/en
Publication of JP2018528200A publication Critical patent/JP2018528200A/ja
Publication of JP2018528200A5 publication Critical patent/JP2018528200A5/ja
Application granted granted Critical
Publication of JP6877407B2 publication Critical patent/JP6877407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510406A 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物 Expired - Fee Related JP6877407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (3)

Publication Number Publication Date
JP2018528200A JP2018528200A (ja) 2018-09-27
JP2018528200A5 true JP2018528200A5 (enExample) 2019-09-12
JP6877407B2 JP6877407B2 (ja) 2021-05-26

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510406A Expired - Fee Related JP6877407B2 (ja) 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物

Country Status (17)

Country Link
US (2) US10017512B2 (enExample)
EP (1) EP3341374A1 (enExample)
JP (1) JP6877407B2 (enExample)
KR (1) KR20180043810A (enExample)
CN (1) CN108137607B (enExample)
AR (1) AR105836A1 (enExample)
AU (1) AU2016311426B2 (enExample)
BR (1) BR112018003588A2 (enExample)
CA (1) CA2995997A1 (enExample)
HK (1) HK1255330A1 (enExample)
IL (1) IL257702A (enExample)
MX (1) MX2018002407A (enExample)
PH (1) PH12018500397A1 (enExample)
RU (1) RU2744974C2 (enExample)
TW (1) TW201713665A (enExample)
WO (1) WO2017035354A1 (enExample)
ZA (1) ZA201801881B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
SI3057969T1 (sl) 2013-10-17 2018-10-30 Blueprint Medicines Corporation Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CN108026102A (zh) 2015-07-24 2018-05-11 蓝印药品公司 可用于治疗与kit和pdgfr相关的病症的化合物
BR112018003588A2 (pt) 2015-08-26 2018-09-25 Blueprint Medicines Corp compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CA3071032A1 (en) 2017-08-23 2019-02-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
WO2019152982A1 (en) * 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic compounds as ep4 antagonists
WO2019184955A1 (en) * 2018-03-28 2019-10-03 Fochon Pharmaceuticals, Ltd. Macrocyclic compounds as trk kinases inhibitors
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
TW202045480A (zh) * 2019-02-27 2020-12-16 美商費洛醫療公司 化合物及使用方法
ES2966512T3 (es) 2019-04-12 2024-04-22 Blueprint Medicines Corp Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251911B1 (en) * 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
EP2890815B1 (en) * 2012-08-31 2019-03-20 The Regents of the University of Colorado Methods for diagnosis and treatment of cancer
WO2014055955A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
CA2899662A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SI3057969T1 (sl) 2013-10-17 2018-10-30 Blueprint Medicines Corporation Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN106536507B (zh) 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
CN108026102A (zh) 2015-07-24 2018-05-11 蓝印药品公司 可用于治疗与kit和pdgfr相关的病症的化合物
BR112018003588A2 (pt) 2015-08-26 2018-09-25 Blueprint Medicines Corp compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Similar Documents

Publication Publication Date Title
JP2018528200A5 (enExample)
RU2018110379A (ru) Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
JP2013544807A5 (enExample)
JP2014520898A5 (enExample)
JP2010501572A5 (enExample)
JP2013522292A5 (enExample)
FI4355749T3 (fi) Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
JP2017537080A5 (enExample)
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
RU2018122089A (ru) Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
JP2019535720A5 (enExample)
JP2019514863A5 (enExample)
JP2019514955A5 (enExample)
JP2017538677A5 (enExample)
UY32251A (es) Compuestos quimicos
JP2015506985A5 (enExample)
JP2020531481A5 (enExample)
RU2012105914A (ru) Эффективные низкомолекулярные ингибиторы аутофагии и способ их применения
PH12017501989A1 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
HK1254469A1 (zh) 稠合双环嘧啶衍生物及其用途
JP2020097631A5 (enExample)
MX2009013591A (es) Proceso para la preparacion de pirazoles.
JP2012504628A5 (enExample)